Both in Pharmaceuticals
Generate Biomedicines vs SELLAS Life Sciences Group
Over the past year GENB returned −11.5% and SLS returned −22.4%; their daily moves had a correlation of 0.10.
GENB −11.5% SLS −22.4%Growth of $1, one year, split-adjusted
| Metric | GENB | SLS |
|---|---|---|
| Price | $13.92 | $8.96 |
| Market cap | $1.79B | $1.81B |
| Today | +0.51% | +1.01% |
| 1 month | +0.9% | −21.0% |
| 6 months | — | +74.0% |
| Year to date | — | +137.7% |
| 1 year | — | +400.6% |
| Revenue growth (YoY) | — | — |
| Gross margin | 100.0% | — |
| Net margin | −1065.2% | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $452.3M | $138.3M |
| Dividend yield | — | — |
| Volatility (60d) | — | 96.8% |
| Short % of float | 15.4% | 27.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).